MorphoSys Receives Two Phase 2 Milestone Payments from Janssen
News Sep 17, 2013
MorphoSys AG has announced that it has received clinical milestone payments from Janssen Biotech, Inc. ("Janssen") following the initiation of two clinical trials.
One trial initiated in asthmatic patients is studying the HuCAL antibody CNTO 3157 and a second trial initiated in patients with active rheumatoid arthritis is studying the HuCAL antibody CNTO 6785. Further financial details were not disclosed.
"The status of our partners' programs is of utmost importance to MorphoSys, as it is an important leading indicator of future earnings potential," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
Dr. Sproll continued, "Our collaboration with Janssen has contributed significantly to our pipeline with clinical candidates in various inflammatory indications and we are delighted to see these two programs advance."
In total, MorphoSys's clinical pipeline now comprises 21 clinical programs. Of these, 17 are programs that were initiated by partners, of which seven are in Phase 1, nine are in Phase 2 and one is in Phase 3 development.
In addition, MOR202, which is being co-developed with Celgene, is in a phase 1/2a trial for multiple myeloma. MOR208, which has concluded a phase 1 trial for chronic lymphocytic leukemia is currently being evaluated in two phase 2 trials in B-ALL and NHL.
MOR103, partnered with GSK, has concluded a phase 1b/2a trial in rheumatoid arthritis, and is currently being evaluated in a phase 1b trial in multiple sclerosis.
Computational Model Underlines Need for Personalised Approach to SepsisNews
A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.READ MORE
Allergies and Asthma Possibly Linked to Female HormonesNews
Fluctuations in female sex hormones could play a role in the development of allergies and asthma, a major review of evidence suggests. Analysis of studies involving more than 500,000 women highlights a link between asthma symptoms and key life changes such as puberty and menopause. Further investigation could help explain why asthma is more common in boys than girls in childhood, but more common in teenage girls and women following puberty.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018